Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 31;9(11):2395.
doi: 10.3390/cells9112395.

Regulation of CAR and PXR Expression in Health and Disease

Martine Daujat-Chavanieu  1 , Sabine Gerbal-Chaloin  1
Affiliations
Review

Regulation of CAR and PXR Expression in Health and Disease

Martine Daujat-Chavanieu et al. Cells. .

Abstract

Pregnane X receptor (PXR, NR1I2) and constitutive androstane receptor (CAR, NR1I3) are members of the nuclear receptor superfamily that mainly act as ligand-activated transcription factors. Their functions have long been associated with the regulation of drug metabolism and disposition, and it is now well established that they are implicated in physiological and pathological conditions. Considerable efforts have been made to understand the regulation of their activity by their cognate ligand; however, additional regulatory mechanisms, among which the regulation of their expression, modulate their pleiotropic effects. This review summarizes the current knowledge on CAR and PXR expression during development and adult life; tissue distribution; spatial, temporal, and metabolic regulations; as well as in pathological situations, including chronic diseases and cancers. The expression of CAR and PXR is modulated by complex regulatory mechanisms that involve the interplay of transcription factors and also post-transcriptional and epigenetic modifications. Moreover, many environmental stimuli affect CAR and PXR expression through mechanisms that have not been elucidated.

Keywords: CAR; PXR; expression; regulation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Yan J., Xie W. A brief history of the discovery of PXR and CAR as xenobiotic receptors. Acta Pharm. Sin. B. 2016;6:450–452. doi: 10.1016/j.apsb.2016.06.011. - DOI - PMC - PubMed
    1. Oladimeji P.O., Chen T. PXR: More than just a master xenobiotic receptor. Mol. Pharmacol. 2017;93:119–127. doi: 10.1124/mol.117.110155. - DOI - PMC - PubMed
    1. Banerjee M., Robbins D., Chen T. Targeting xenobiotic receptors PXR and CAR in human diseases. Drug Discov. Today. 2015;20:618–628. doi: 10.1016/j.drudis.2014.11.011. - DOI - PMC - PubMed
    1. Mackowiak B., Hodge J., Stern S., Wang H. The roles of xenobiotic receptors: Beyond chemical disposition. Drug Metab. Dispos. 2018;46:1361–1371. doi: 10.1124/dmd.118.081042. - DOI - PMC - PubMed
    1. Xiao L., Nickbarg E., Wang W., Thomas A., Ziebell M., Prosise W.W., Lesburg C.A., Taremi S.S., Gerlach V.L., Le H.V., et al. Evaluation of in vitro PXR-based assays and in silico modeling approaches for understanding the binding of a structurally diverse set of drugs to PXR. Biochem. Pharmacol. 2011;81:669–679. doi: 10.1016/j.bcp.2010.12.003. - DOI - PubMed

Publication types

LinkOut - more resources